How Successful Investors Get RICH

Learn everything you need to know in 'The Canadian Guide on How to Invest in Stocks Successfully' for FREE from The Successful Investor.

How to Invest In Stocks Guide: Find 10 factors that make your investments safer and stronger.

 I consent to receiving information from The Successful Investor via email. I understand I can unsubscribe from these updates at any time.

Topic: How To Invest

Rising drug firm aims to break through with ‘bad cholestrol’ drug

Rising drug firm aims to break through with ‘bad cholestrol’ drug

Pat McKeough responds to many requests from members of his Inner Circle for specific advice on stocks to buy as well as questions on investment strategy and the economy. Every week, his comments and recommendations on the most intriguing questions of the past week go out to all Inner Circle members. And each week, we offer you one of the highlights from these Q&A sessions. While we reserve our buy-hold-sell advice for Inner Circle members, these excerpts provide a great deal of information and analysis on stocks we’ve covered for members of Pat’s Inner Circle.

This week we had a question from an Inner Circle member about a medical stock that specializes in the treatment of cholesterol. With its shares on the stock market for less than a year and a founder who has a strong reputation in the field, Esperion Therapeutics is developing a drug aimed at blocking a major contributor to cholesterol. Pat examines the specific strain of cholesterol the drug is designed to combat and looks at the company’s progress with the drug. He also considers the risk Esperion runs from competitors and from possible setbacks in the long testing process.

Q: Pat: Can I have your recommendation on Esperion Therapeutics? Thanks.

A: Esperion Therapeutics (symbol ESPR; www.esperion.com), develops treatments for patients with elevated levels of low-density lipoprotein cholesterol (LDL-C).

LDL-C, known as “bad cholesterol,” can collect in the walls of blood vessels, causing blockages in arteries. Higher LDL-C levels can increase the risk of a heart attack.

The company first sold shares to the public at $14 each and began trading on Nasdaq on June 26, 2013. It trades today at $16.

ETC-1002, Esperion’s lead development drug, is designed to lower LDL-C levels and avoid side effects associated with existing LDL-C therapies, known as statins.

Esperion founder played important role in the development of best-selling Lipitor

The company has designed ETC-1002 for statin-intolerant patients with higher LDL-C levels. Statins work by blocking a substance the body needs to make cholesterol. They may also help the body reabsorb cholesterol that has built up in the form of plaque on artery walls, preventing further blockage and heart attacks.

Common statins on the market include atorvastatin (Lipitor), simvastatin (Zocor), lovastatin (Mevacor), pravastatin (Pravachol) and rosuvastatin (Crestor).

ETC-1002 slows cholesterol production in the liver, but at an earlier stage than statins. Esperion has completed seven clinical studies on ETC-1002, including four Phase 2A studies, and has started a Phase 2B clinical program.

Esperion has attracted a lot of investor attention because its founder and chairman, Roger Newton, was a key member of the team that developed atorvastatin (Lipitor) for Pfizer. Lipitor is one of the best-selling drugs ever.

In the Inner Circle Q&A, Pat looks at whether Esperion’s cash reserves will let it continue developing ETC-1002 on its own or whether it will have to take on a major partner. He also examines the prospects of success for early stage drugs. He concludes with his clear buy-hold-sell advice on this stock.

(Note: If you are a current member of the Inner Circle, please click here to view Pat’s recommendation. Be sure to log in first.)

COMMENTS PLEASE—Share your investment experience and opinions with fellow TSINetwork.ca members

Have you invested in a pharmaceutical stock because it had a high-profile best-selling drug? Did the stock continue to do well for you after patent protection ran out for that drug? Have you ever taken a chance with a less-established firm that looked like it might achieve a breakthrough with an important new drug? Did that pay off for you?

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.